Manufacturer
ROCHE DIAGNOSTICS GMBH
Contents
Epoetin β
Indication
Anemia associated w/ chronic renal failure (CRF) in patients on dialysis. Symptomatic treatment of renal anemia in pre-dialysis patients. Anemia w/ solid tumours & treated w/ platinum-based chemotherapy prone to induce anemia. Symptomatic treatment of anemia w/ multiple myeloma, low grade non-Hodgkin's lymphoma or chronic lymphocytic leukemia in adults w/ relative erythropoietin deficiency & receiving anti-tumor therapy. Increasing yield of autologous blood from patients in pre-donation program. Prevention of anaemia in premature infants <34 wk w/ 750-1,500 g birth wt.
Instruction
Anemia w/ CRF Correction phase: SC inj Initially 3 x 20 IU/kg/wk, may be increased every 4 wk by 3 x 20 IU/kg/wk if increase is inadequate <0.25 g/dL/wk. Wkly dose can be divided into daily doses. IV inj Initially 3 x 40 IU/kg/wk, may be increased after 4 wk to 80 IU/kg 3 times wkly. Further increased at 20 IU/kg increments if needed 3 times wkly at mthly intervals. Max dose: Not to exceed 720 IU/kg/wk. Maintenance phase: Initially reduced to ½ of previously administered amount. Adjust dose subsequently at 2-4 wk intervals individually. Prevention of anemia of prematurity SC inj 3 x 250 IU/kg/wk for 6 wk. Symptomatic treatment of anemia in cancer SC inj Initially 30,000 IU/wk (approx 450 IU/kg/wk based on ave wt) for 4 wk. If Hb value increased by at least 1 g/dL, continue therapy; if not, double wkly dose. After 8 wk therapy, if Hb value has not increased by at least 1 g/dL, discontinue therapy. Continue therapy up to 4 wk after end of chemotherapy. Max: Not to exceed 60,000 IU/wk. SC/IV inj Increasing amount of autologous blood Individualized dosage administered twice wkly over 4 wk. Max IV Dose: 1,600 IU/kg/wk. Max SC Dose: 1,200 IU/kg/wk.
Drug interaction
No dedicated clinical interaction studies have been performed.
Clinical experience has not given evidence for potential interaction of Recormon with other medicinal products (for more information see also Pharmacology: Toxicology: Nonclinical Safety: Other under Actions).
In animal experiments epoetin did not increase the myelotoxicity of cytostatic medicinal products like etoposide, cisplatin, cyclophosphamide and fluorouracil.
Malaysia
